Abstracts tagged "synovium and tocilizumab"

Abstract Number: 2869 • 2017 ACR/ARHP Annual Meeting
Significant Decrease of T-Cells but Not Macrophages in the Synovium of Patients with Active Rheumatoid Arthritis after Treatment with Tocilizumab
Katerina Chatzidionysiou¹, Marianne Engström¹, Erik af Klint¹, Aase Hensvold¹ and Anca I Catrina², ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Tocilizumab (TCZ) is an anti-IL6R monoclonal antibody approved for the treatment of Rheumatoid Arthritis (RA). There is limited data on synovial tissue histology changes.…
Abstract Number: 3099 • 2015 ACR/ARHP Annual Meeting
Differential Effects of IL-6 Blockade Tocilizumab and TNF Inhibitors on the Reduced Angiogenesis and Lining Layer Degeneration in Synovial Tissues from Patients with Rheumatoid Arthritis
Hirohata Shunsei¹, Asami Abe^2,3, Akira Murasawa³, Tetsuya Tomita⁴ and Hideki Yoshikawa⁴, ¹Rheumatology and infectious diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Rheumatplogy, Niigata Rheumatic Center, Shibata, Japan, ³Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ⁴Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by hyperplasia of synovial tissues, leading to the destruction of joint structures. TNF inhibitors, including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].